 | 2010-Apr-20
Press Release |
 |
ForteBio Launches New-Generation Octet® QKe Instrument | | [show details] |
|
| MENLO PARK, Calif. — April 20, 2010 — ForteBio®, Inc., a leading supplier of label-free technology that accelerates the development of biotherapeutic and pharmaceutical products, today announced the launch of its new Octet QKe instrumentation system. The new system, the next generation of the company’s initial eight-channel Octet QK instrument, provides significantly increased sensitivity, enabling analysis of small proteins and peptides. Additiona...
More... |
|
| 2010-Mar-09
News |
|
Tecan and ForteBio Automate Label-Free assays for Bioprocess and Drug Discovery Applications | | [show details] |
|
| Tecan has become ForteBio’s preferred automation partner for real-time, label-free assays to support bioprocess and drug discovery workflows. The two companies have worked together to integrate the new ForteBio Octet® 384 platform, consisting of the Octet RED384 and the Octet QK384, on Tecan’s Freedom EVO® liquid handling workstation. The result is a robust, off-the-shelf integration that offers increased walkaway time and optional liquid handling for assay plate set-up.More... |
|
| 2010-Jan-11
Press Release |
|
ForteBio Launches New Dip and Read™ Residual Protein A Detection Kit; Introduces Sidekick™ Offline Biosensor Immobilization Station for all Octet® Instruments | | [show details] |
|
| MENLO PARK, Calif. — January 11, 2010 — ForteBio®, Inc., a leading supplier of label-free technology that accelerates the development of biotherapeutic and pharmaceutical products, today announced the launch of its new Dip and Read Residual Protein A Detection Kit for use on the company’s Octet platform. The new assay enables drug developers to accurately identify and measure levels of Protein A with unprecedented speed and minimal hands-on time. The company a...
More... |
|
| 2009-Sep-16
Press Release |
|
ForteBio Launches Dip and Read™ Immunogenicity Assay Kit for Rapid Detection of Anti-Drug Antibodies | | [show details] |
|
| MENLO PARK, Calif. — September 16, 2009 — ForteBio®, Inc., a leading supplier of label-free technology that accelerates the development of biotherapeutic and pharmaceutical products, announced today that it has launched the new Dip and Read Immunogenicity Assay Kit for rapid
detection of anti-drug antibodies (ADA) for use on the company's Octet® platform. The new assay kit provides life science researchers with new levels of throughput, speed and flexibility for measurin...
More... |
|
| 2009-Jun-22
Press Release |
|
ForteBio Launches Two Revolutionary High-Throughput, Label-Free Instruments: The Octet® RED384 and The Octet QK384 | | [show details] |
|
| MENLO PARK, Calif. — June 22, 2009 — ForteBio, Inc., a leading supplier of label-free technology that accelerates the development of biotherapeutic and pharmaceutical products, announced today that it has launched two next-generation instruments: the Octet RED384 for protein, peptide, small molecule and fragment screening; and the Octet QK384 for protein and antibody assays. The new instruments will début this week at the 2009 American Association of Pharmaceutical Scientis...
More... |
|
| 2009-May-26
Press Release |
|
ForteBio Launches New Assay Capabilities for High-Sensitivity Protein Quantitation and Fragment Screening on its Octet® Platform | | [show details] |
|
| MENLO PARK, Calif.— May 27, 2009— ForteBio®, Inc., a leading supplier of label-free technology that accelerates the development of biotherapeutic and pharmaceutical products, today announced that it has launched two new assay modules — for high-sensitivity protein quantitation and fragment screening, respectively — for use on the company's Octet® instrumentation platform. The new modules are available via software upgrades and will enable, for the first time, l...
More... |
|
| 2009-Mar-03
Press Release |
|
ForteBio Launches New Biosensor for Kinetic Analysis and Screening of Human IgG Antibodies | | [show details] |
|
| MENLO PARK, Calif. — March 3, 2009 — ForteBio®, Inc., a leading supplier of label-free technology that accelerates the development of biotherapeutic and pharmaceutical products, today announced the launch of its Anti-Human IgG Fc Capture (AHC) biosensor for use on the company’s Octet® instrumentation platform. The new biosensor enables more cost-effective, easy-to-use and rapid kinetic characterization and screening of human lgG antibodies and other Fc-containing pro...
More... |
|
| 2008-Sep-23
Press Release |
|
ForteBio, Inc. Closes $25 Million in Series C Financing | | [show details] |
|
| MENLO PARK, Calif. September 23, 2008 — ForteBio®, Inc., a leading supplier of label-free technology that accelerates the development of life science and pharmaceutic products, today announced the closing of $25 million in Series C financing, led by OrbiMed Advisors, a top global healthcare investment firm. MPM Capital also participated as a new investor in this financing round, as did existing investors Alloy Ventures, Versant Ventures, The Vertical Group and La...
More... |
|
| 2008-Apr-03
Press Release |
|
ForteBio Announces New Octet RED System for Drug Candidate Characterization and Selection | | [show details] |
|
| MENLO PARK, Calif. - April 3, 2008 — ForteBio®, Inc., a life science company that develops and sells analytical tools to accelerate the development of therapeutic products, today announced the launch of the Octet® RED System, for label-free, real-time kinetic analysis of drug compounds. The new system brings unparalleled ease-of-use, sensitivity, throughput and affordability to the analysis of small molecules, peptides and proteins for research, development and bioprocess...
More... |
|
| 2007-Sep-18
Press Release |
|
ForteBio Announces Executive Change | | [show details] |
|
| MENLO PARK, Calif. — September 18, 2007 — ForteBio, Inc., a rapidly growing life science company that develops and commercializes analytical instruments and consumables to accelerate and improve therapeutics development, announced today that Joseph D. Keegan, Ph. D., has been named president and chief executive officer, beginning September 24, 2007. ForteBio founding CEO Winnie H. Wan, Ph.D., who is credited with building the company into an emerging leader in the label-fr...
More... |
|
| 2007-Aug-20
Press Release |
|
ForteBio Expands International Distribution Network | | [show details] |
|
| MENLO PARK, Calif. — August 20, 2007 — ForteBio, Inc., a leading developer of label-free, real-time systems for biomolecular interaction analysis, announced today that it has signed two new distributors to sell and distribute its Octet System of instruments and related consumables. The company named Bucher Biotec AG, Switzerland, as its exclusive Swiss distributor and Millennium Science Pty Ltd, Australia, as its distribution partner in Australia and New Zealand. The annou...
More... |
|
| 2007-Aug-13
Press Release |
|
ForteBio Strengthens Portfolio with New Biosensors for Research and Development | | [show details] |
|
| MENLO PARK, Calif. — August 13, 2007 — ForteBio, Inc., a leading developer of label-free, real-time systems for biomolecular interaction analysis, today announced two new product extensions to its Octet™ System. The Anti-Murine IgG Biosensor — Quantitation grade, and the Streptavidin High Binding FA Biosensor — Screening grade, extend the Octet System's concentration determination and kinetic analysis capabilities, respectively, broadening the product off...
More... |
|
| 2007-Jun-29
Product Bulletin |
|
New Biosensors expand applications for research and assay development | | [show details] |
|
| In ForteBios' continuing effort to expand the applications on the Octet System, we are launching two new biosensors for the kinetic analysis and concentration determination for research, development and production of antibody and protein therapeutics.
The following Screening and Quantitation grade biosensors are now available for use on the Octet System.
Anti-Murine IgG Biosensors - Quantitation Grade
• Determine mouse or rat IgG concentration based on a st...
More... |
|
| 2006-Dec-07
Press Release |
|
ForteBio Launches New Biosensors to Increase the Flexibility of the Octet System | | [show details] |
|
| MENLO PARK, Calif. — December 7, 2006 — ForteBio, Inc. announced today the launch of the Amine Reactive and Protein A Biosensors for use on ForteBio's Octet System, a label-free, real-time detection system for the analysis of molecular interactions. The new biosensors expand the menu of Octet applications, providing convenient kinetic analysis and concentration determination for the development of antibody and protein therapeutics.
The ForteBio Octet System is cur...
More... |
|
| 2006-Jul-18
Press Release |
|
ForteBio Adds Bernelle Saperstein to its Management Team | | [show details] |
|
| MENLO PARK, Calif. — July 18, 2006 — ForteBio, Inc., developer of label-free systems for real-time detection and analysis of molecular interactions, said today that Bernelle H. Saperstein has joined the company as Vice President, Manufacturing Operations, a new position. Ms. Saperstein comes to ForteBio from BD-Immunocytometry Systems, where she led a large team responsible for manufacturing and testing reagents for cell analysis.
“Bernelle is an extremely...
More... |
|
| 2005-Nov-29
Press Release |
|
ForteBio Introduces the Octet System
for Antibody and Protein Therapeutics Development | | [show details] |
|
| MENLO PARK, Calif. — November 29, 2005 — ForteBio, Inc. today announced the commercial introduction of the company's first product, the Octet™ System for label-free, real-time detection and analysis of molecular interactions. The next generation of analytical tools for life science research, Octet accelerates antibody development by generating real-time quantitative and kinetics results quickly and easily. Ready to use, consumable biosensors provide a cost-effective...
More... |
|
| 2005-Oct-26
Press Release |
|
ForteBio Raises 17.3 Million in Series B Financing - Funding Will Support Launch | | [show details] |
|
| MENLO PARK, Calif. — October 26, 2005 — ForteBio, Inc., a life sciences company
providing tools for the detection and analysis of biomolecules and their interactions, today
announced the close of a $17.3 million Series B Preferred Stock financing. The round was
led by The Vertical Group, a New Jersey-based venture capital firm that is focused on the
fields of medical technology and biotechnology. All of the company's existing investors,
Agilent Ventures, Alloy Ventures...
More... |
|
